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INTRODUCTION
Breast cancer does not induce significant immune
responses that effectively destroy malignant cells [19].
However, given the evidence of T cell-mediated
immunosurveillance [22] based on the recognition of
epitopes from tumor-associated antigens (TAAs) [21], it
is of interest to quantify the immune responses that
appear in cancer patients. As both spontaneous and
induced T cell responses may influence the clinical
course and the outcome of the patient [14], this evalua-
tion might contribute to a better assessment of the prog-
nosis of the disease. It also provides further insight into
ways to optimize the design of immunotherapeutic
strategies [1].
The tumor antigen mucin 1 (MUC1, CD 227), encod-
ed by the MUC1 gene, is a large, heavily glycosylated,
transmembrane protein expressed on the apical surface
of mucosal epithelial cells [9]. MUC1 has been consid-
ered as a potential target for immunotherapy as its
expression is changed, with the glycoprotein becoming
shorter and less branched, in cells that have undergone
malignant transformation, leading to the exposure of pre-
viously masked epitopes [4]. One of the MUC1-derived
epitopes, peptide MUC1950–958 (STAPPVHNV), has been
proven to induce a T cell response in vitro and subse-
quently to trigger ex vivo lysis of tumor cell lines [3]. The
peptide is localized in the tandem repeat region of MUC1
and is presented on the cell surface in an HLA-A*0201-
-restricted manner [3]. In cancer patients, cellular
immune responses against several other MUC1-derived
peptides have been reported [6], but the precursor fre-
quencies of the CD8+ T cells recognizing the MUC1950–958
epitope circulating in the peripheral blood have so far not
been extensively evaluated in breast cancer patients. 
Several assays have been developed to monitor
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allows the quantification of antigen-specific cells inde-
pendently of their functional properties with a sensitivi-
ty of 1:50,000, whereas the interferon (IFN)-γ secretion
assay quantifies a specific cytokine response to TAAs.
Both methods combined provide a comprehensive pic-
ture of the frequency and function of tumor-specific
T cells. We examined the immunogenicity of the
MUC1950–958 peptide in breast cancer patients by quanti-
fying the epitope-specific CD8+ T cells.
MATERIALS AND METHODS
Patients
Breast cancer patients referred to the outpatient’s unit
of the Medical Clinic for Hematology and Oncology,
Charité Berlin, were randomly screened for the presence
of HLA-A2 following informed consent. From a cohort of
19 HLA-A2-positive patients, blood samples were
obtained for the evaluation of immune response. Tumor
grade, axillary node status, and previous treatment of the
patients were recorded over a time period of 30 months
(Table 1). Most of the patients had been pretreated by
surgery, radiation, or multiple cycles of chemotherapy.
None of the patients had received chemotherapy or radio-
therapy within the four weeks prior to sample collection.
Cell culture
Peripheral blood mononuclear cells (PBMCs) were
isolated from heparinized blood by density gradient cen-
trifugation using Lymphoprep™ (1.077 g/ml; Biochrom,
Berlin, Germany), washed, and cultured overnight in
RPMI medium (Biowhittaker, Verviers, Belgium) sup-
plemented with 10% FCS, 2 mM L-glutamin, 100 U/ml
penicillin, and 100 µg/ml streptomycin at 37°C in 5%
CO2-cell counting and the tetramer and IFN-γ assays
were performed the next day.
Tetramer assay
Phycoerythrin (PE)-conjugated tetrameric complex-
es consisting of HLA-A*0201 and STAPPVHNV pep-
tide were purchased commercially (Proimmune,
Oxford, UK). Additionally, HIV gag-derived SLYNT-
VATL peptide (Proimmune, Oxford, UK) was used as
a negative control. Approximately 1–2 million PBMCs
from each patient were stained with tetramers for 30
min at room temperature followed by staining with an
FITC-conjugated antihuman CD8 monoclonal antibody
(mAb; Becton Dickinson, Heidelberg, Germany).
Quadrant analysis was applied to determine the per-
centage of tetramer-positive CD8+ T cells.
IFN-γ assay
PBMCs were stimulated for 5 h with 10 µg/ml of the
mucin peptide containing the STAPPVHNV sequence
(Biosyntan, Berlin, Germany) in RPMI-1640 medium
supplemented with 10% AB serum and cultured at
37°C in 5% CO2. An unstimulated sample containing
the same amount of cells was used as a negative control.
At least one million PBMCs were washed and resus-
pended in 90 µl of cold medium. Ten µl of the IFN-γ-
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Table 1. Clinical features of the breast cancer patients
Patient number Age/sex Stadium at diagnosis Prior treatment Metastases Clinical course
1 77/f pT1pN1M1 G3 S M (L, B) † PD
2 35/f cT2cN1M0 G2 C+S free CR
3 82/f pT1pNxM1 G2 C+S+R M (L) SD
4 76/m cT2cN1M1 Gx ST M (B) SD
5 53/f pT1pN1M1 Gx C M (P) † PD
6 63/f pT3pN1M1 G3 C+S M (L, B, P) PD
7 68/f pT1pN0M1 G3 C+S+R M (brain) † PD
8 60/f pT4pN1M1 G3 C+S M (P) SD
9 75/f pT3pN1M1 G2 C+S M (LN) PD
10 45/f cT3cN1M0 G3 C+S NA NA
11 33/f cT3cN0M0 G2 C+S+R free CR
12 76/f pT1pN0M1 G2 C M (L, B, S) † PD
13 50/f pT2pN0M1 G3 S+R M (P) PD
14 71/f pT4pN1M1 G2 C+S+R M (B) SD
15 60/f pT2pN1M1 G2 C+S M (B) † PD
16 52/f pT1pN1M1 G3 C+S M (L, P, B) PD
17 39/f cT2cN0M0 G1 C+S free CR
18 44/f pT2pN2M0 G3 C+S free CR
19 66/m cT4cNxM1 Gx C+R M (P, B) PD
Gx – grade unknown, C – chemotherapy, R – radiation, S – surgery, ST – supportive therapy, NA – not available, M – metastases,
L – liver, B – bone, P – lung, S skin, LN – lymph node, † – death, PD – progressive disease, CR – complete remission, SD – stable
disease, f – female, m – male.-catch reagent (Miltenyi Biotec, Bergisch Gladbach,
Germany) were added and incubated for 5 min on ice.
Subsequently, 10 ml of warm medium were added and
the IFN-γ secretion assay was performed by incubation
at 37° for 45 min. Sedimentation of the cells was pre-
vented by inverting the tubes every 5 min. After 45 min,
5 ml of cold PBS buffer (GIBCO BRL, Life Island,
USA) containing 0.5% BSA (Sigma, Munich, Germany)
and 2 mM of EDTA (Sigma) was added to each tube
and the cells were centrifuged for 15 min at 300×g and
4°C. The supernatants were completely removed and
the cells were resuspended in 80 µl of ice-cold buffer.
Ten  µl of the PE-labeled anti-IFN-γ mAb (Miltenyi
Biotec) and 10 µl of the FITC-labeled mAb specific to
CD8 (Becton Dickinson, Heidelberg, Germany) were
added and incubated for 15 min on ice. Finally, 10 ml of
cold buffer were added and the cells were centrifuged
for 15 min at 300×g and 4°C. Propidiumiodid (Sigma)
was added to each sample to a final concentration of
1 µg/ml to exclude dead cells from the analysis. 
Samples from both the tetramer and IFN-γ assays
were subsequently analyzed by flow cytometry using
a FACS-Calibur (Becton Dickinson) and CellQuest
software. Background values from unstimulated control
cells were subtracted.
RESULTS
Tetramer assay
The CD8+ T cell-frequency against specific peptides
was evaluated using tetramer analysis of the PBMCs
from cancer patients. Frequencies ranging from 0 to 9
CD8+ T cells per 105 PBMCs were assessed as the back-
ground (Table 2). CD8+ T cells capable of recognizing
the MUC1950–958 peptide were identified in 9 of the 19
patients (Table 2). In the positive samples, the frequen-
cy of HLA-A2-MUC1-specific CD8+ cells in the
PBMCs ranged from 0.01 to 0.082%. Figure 1 shows the
results of the patient with the strongest cellular response
specific to MUC1950–958.
HLA-A2-HIV-specific CD8+ T cells were not
detectable in 14 of 18 patients. However, four patients
revealed frequencies of HIV-epitope-specific T cells
ranging from 0.01 to 0.016%. 
IFN-γ assay
The amount of released IFN-γ from the PBMCs of
the five patients who showed significant responses in the
tetramer assay (patients 1, 3, 4, 11, 14) was smaller than
0.01%, which was defined as the background (Table 3).
Clinical course
Ten of the 19 patients progressed in their tumor dis-
ease, four patients remained stable, in four patients the
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Table 2. Number of tetramer-binding CD8+ T cells
Patient Number of tetramer-positive CD8+ cells/105 PBMCs
number HIV MUC1950–958
14 26
24 6
3 10 15
40 40
55 5
6 10 7
7N D 4
8 13 10
90 10
10 0 0
11 2 30
12 7 4
13 3 6
14 16 82
15 1 1
16 2 29
17 0 3
18 7 3
19 7 15
The numbers in bold represent specific frequencies.
ND – not determined.
Fig. 1. Example depicting the strongest
immune response against MUC1 which could
be detected in the breast cancer patients. The
frequency of specific T cells was evaluated
using the tetramer assay. PBMCs were stained
with HIV- or MUC1950–958-loaded HLA-
-A*0201-specific tetramers. The cells were
then stained with an FITC-labeled anti-CD8
mAb. An HIV-derived peptide served as the
negative control.
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0.082%disease was not detectable, and in one patient the clini-
cal course could not be followed (Table 1).
Four patients with progressive disease had
detectable MUC1-specific CD8+ T cells and six patients
did not (Tables 1 and 2). All four patients with stable
disease stained tetramer positive, including both the
patients with the highest frequency. Three of the four
disease-free patients had no tumor-specific T cells. The
patients with stable disease showed a significantly high-
er MUC1-specific CD8+ T cell frequency than the
patients with progressive disease (p=0.046) as detected
by two-sided Student’s t-test. There was no significant
difference in MUC1-specific frequency between the dis-
ease-free patients and the patients with stable or pro-
gressive disease.
DISCUSSION
The data presented in this report demonstrate the
existence of CD8+ T cells against MUC1950–958 peptide
in 46% of the analyzed breast cancer patients as detect-
ed by tetramer assays. This result is in accordance with
the findings of Choi et al. [5] in patients with multiple
myeloma and Rentzsch et al. [20], who were able to
detect MUC1950–958-specific T cell responses in a similar
percentage of breast cancer patients by quantifying the
amount of IFN-γ-specific mRNA after peptide stimula-
tion. Recently, Gûckel et al. [11] observed MUC1950–958-
-specific T cells to a similar extent, mainly in patients in
an early stage of disease. The CD8+ T cell frequencies
are lower than previously described for other MUC1
epitopes [6], where frequencies were between 0.2% and
1%. In our study, the presence of a specific T cell popu-
lation which includes CD8+ NK- and NK-T cells in a fre-
quency ranging from 0.01 to 0.082% against the
MUC1950–958 peptide suggests that the investigated pep-
tide can be recognized on the surface of breast cancer
cells. However, although 92% of the breast cancer cases
expressed MUC1, more than half of the patients failed
to generate a spontaneous T cell response against the
MUC1950–958 peptide [7, 10]. The peptide presentation
may vary considerably among patients [15]. Insufficient
peptide presentation due to a reduction or absence of
the MHC I presentation pathway or the downregulation
of the transporter protein associated with antigen pre-
sentation in the HLA complex in breast cancer cells,
which are frequently observed in breast cancer, may
result in weak T cell responses [2, 12]. Furthermore, low
avidity of the T cell receptor (TCR), decreased expres-
sion of the TCR ζ-chain, or the suppression of T cells
either by previous therapy or by cytokines secreted by
tumor cells may account for a weak or absent immune
response [19, 24]. Moreover, it is possible that the fre-
quency of naturally existing MUC1950–958-specific T cells
lies below the sensitivity of the tetramer assay.
Interestingly, four patients showed a specific T cell
response against the HIV gag epitope. However, a study
by Kan-Mitchell et al. [13] showed that uninfected indi-
viduals also possess T cells which are able to recognize
this peptide.
In our experiments, the T cells were not able to pro-
duce IFN-γ after stimulation with the MUC1950–958 pep-
tide. This finding is consistent with the results of previ-
ous studies in which the existence of peripherally circu-
lating, tumor-reactive cells has been reported, but the
use of functional assays such as ELISPOT often failed to
detect TAA-specific responses [8, 16, 17]. Presumably,
in cancer patients functional CD8+ T cells could be
localized in the lymph nodes and not in the peripheral
blood. Furthermore, the loss of effector function could
be due to anergy of specific T cells.
We evaluated further whether the frequencies of
MUC1950–958-specific T cells measured by the tetramer
assay influenced the clinical course of the patients. No
significant difference was found between the occurrence
of epitope-specific CD8+ T cells of patients with pro-
gressive disease and disease-free patients. However, all
patients with stable disease showed an immune
response. Similar results were reported for the evalua-
tion of a pre-existing T cell immune response in patients
with breast cancer or other tumor types [18, 20, 23].
In summary, there were specific T cells against the
MUC1950–958 peptide detectable in nearly the half of the
investigated breast cancer patients.
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